Uterine Corpus Neuroendocrine Neoplasm
NCI Definition: An epithelial neoplasm with neuroendocrine differentiation that arises from the uterine corpus. It includes carcinoid tumor, small cell carcinoma pulmonary type, and large cell neuroendocrine carcinoma. 
Uterine corpus neuroendocrine neoplasms most frequently harbor alterations in TP53, PIK3CA, RB1, PTEN, and NOTCH1 .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, PIK3CA Mutation, and PTEN Mutation are the most common alterations in uterine corpus neuroendocrine neoplasm .
There are 5 clinical trials for uterine corpus neuroendocrine neoplasm, of which 3 are open and 2 are completed or closed. Of the trials that contain uterine corpus neuroendocrine neoplasm as an inclusion criterion, 2 are phase 1 (2 open) and 3 are phase 2 (1 open).
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in uterine corpus neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.